Structured Support Limits Weight Regain After GLP-1 Discontinuation

What the Pilot Trial Evaluated

A pilot randomized controlled trial evaluated whether structured interventions mitigate weight regain after stopping glucagon-like peptide-1 (GLP-1) receptor agonists.

Investigators followed 39 adults who achieved weight loss before discontinuing the medication.

At the time of drug cessation, researchers randomly assigned participants to four months of usual care, a digital wellness application, or medically tailored meals.

Weight Regain Across the Study Groups

Participants receiving structured support experienced less weight regain than those assigned to standard care.

Over four months, control subjects gained an estimated 10.75 percent of their body weight.

Participants using the digital wellness application gained 3.60 percent, while the medically tailored meals group gained 3.58 percent.

• Usual care group: 10.75 percent estimated weight regain
• Digital wellness application group: 3.60 percent estimated weight regain
• Medically tailored meals group: 3.58 percent estimated weight regain

Patient Satisfaction and Secondary Outcomes

Surveys revealed no statistically significant differences in diet quality, perceived health, adherence, or satisfaction among the study arms.

Satisfaction ratings remained generally comparable across all three cohorts.

Researchers at the Tufts University Food is Medicine Institute noted minor non-significant trends favoring the digital wellness tool on select survey measures.

Context and Study Limitations

Discontinuation of GLP-1 therapy is common in clinical practice due to high costs, insurance coverage limits, adverse side effects, or patient preference.

Weight regain frequently follows when patients stop these therapies without structured behavioral assistance.

Patients considering stopping a GLP-1 agonist should discuss nutrition and maintenance planning with a qualified clinician.

• The small sample of 39 participants limits the statistical power of secondary survey comparisons.
• The four-month observation window tracks early outcomes rather than multi-year weight maintenance.
• Further randomized trials are required to confirm these maintenance strategies across larger populations.